Company / Cash & Equivalents
Esperion Therapeutics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$167.9M
FY2025
5-year range
$82.2M / $208.9M
FY2021-FY2025
Trend
+16.0%
vs FY2024
Sector context
#103 of 207
Health Care
What the data says
At $168M, Esperion Therapeutics, Inc.'s cash & equivalents ranks #103 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $34M in FY2017 to $305M in FY2020.
Based on SEC 10-K filings.
$168M in FY2025 with a 5-year CAGR of -11.3%.
Improved from $82M to $168M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +10.4%
- 5-Year CAGR
- -11.3%
- 10-Year CAGR
- -
Sector benchmark
#103 of 207 in Health CareTop 50% of 207This company $167.9M Sector average $669.5M
▼
-74.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -11.3%, indicating a declining trend.
- In FY2025, cash & equivalents increased 16.0% year-over-year.
- Ranks #103 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $167.9M | +16.0% |
| FY2024 | $144.8M | +76.0% |
| FY2023 | $82.2M | -34.1% |
| FY2022 | $124.8M | -40.3% |
| FY2021 | $208.9M | -31.5% |
| FY2020 | $305.0M | +83.6% |
| FY2019 | $166.1M | +349.3% |
| FY2018 | $37.0M | +7.3% |
| FY2017 | $34.5M | -9.7% |
| FY2016 | $38.2M | -50.7% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026